Hydroxyurea (HU) is an antitumor agent effective in the treatment of myeloproliferative disorders. It is usually well-tolerated and has low toxicity but its use is associated with several adverse cutaneous effects. Among them, leg ulcers have been noted in association with long-term administration. Poor response to traditional local and systemic therapy is a typical feature of HU-induced leg ulcers, and discontinuation of the drug is often required to achieve complete wound healing. We present a case of circumferential HU-induced leg ulcer in a patient affected by essential thrombocythemia, in which the lesion occured after the definitive suspension of the treatment. We propose a conservative management with a new collagennse (Bionect Start (R)) for skin lesions in this type of patient, for whom a surgical treatment could be more complicated, due to the underlying disease.
A Case of Hydroxyurea-induced Leg Ulcer after Definitive Treatment Suspension in a Patient Affected by Thrombocythemia: Effectiveness of a New Collagenase / Fioramonti, Paolo; Fino, Pasquale; Parisi, Paola; Scuderi, Nicolo'; Onesti, Maria Giuseppina. - In: IN VIVO. - ISSN 0258-851X. - 26:6(2012), pp. 1053-1056.
A Case of Hydroxyurea-induced Leg Ulcer after Definitive Treatment Suspension in a Patient Affected by Thrombocythemia: Effectiveness of a New Collagenase
FIORAMONTI, Paolo;FINO, PASQUALE;PARISI, PAOLA;SCUDERI, Nicolo';ONESTI, Maria Giuseppina
2012
Abstract
Hydroxyurea (HU) is an antitumor agent effective in the treatment of myeloproliferative disorders. It is usually well-tolerated and has low toxicity but its use is associated with several adverse cutaneous effects. Among them, leg ulcers have been noted in association with long-term administration. Poor response to traditional local and systemic therapy is a typical feature of HU-induced leg ulcers, and discontinuation of the drug is often required to achieve complete wound healing. We present a case of circumferential HU-induced leg ulcer in a patient affected by essential thrombocythemia, in which the lesion occured after the definitive suspension of the treatment. We propose a conservative management with a new collagennse (Bionect Start (R)) for skin lesions in this type of patient, for whom a surgical treatment could be more complicated, due to the underlying disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.